ITX24-01 in Adult Male and Female Patients With Select Types of Severe Chronic Neck- and Lower Ba… (NCT07520240) | Clinical Trial Compass
Not Yet RecruitingPhase 1
ITX24-01 in Adult Male and Female Patients With Select Types of Severe Chronic Neck- and Lower Back Pain
Australia32 participantsStarted 2026-06-01
Plain-language summary
The study is a single ascending dose (SAD), single-center, randomised, double-blind, placebo-controlled Phase 1b clinical trial designed to evaluate the safety, tolerability, and preliminary analgesic efficacy of ITX24-01 in patients with severe chronic zygapophysial joint pain (facet joint pain). The study consists of three dose escalation cohorts and one extension cohort.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Male or female. Women of childbearing potential must be willing to use contraceptives, or not be sexually active from the time when, during screening, pregnancy was excluded (by history and/or pregnancy test) until after the day of treatment has been completed (until ≥6 hours after administration of the IMP).
✓. Age ≥18 years
✓. Diagnosis of chronic zygapophysial joint neck- or lower back pain and elected to undergo medial branch neurotomy (MBN), aka radiofrequency ablation (RFA), as treatment for that pain syndrome. Participants can be patients who have undergone prior MBN (at the same level and side) and who have experienced pain recurrence and have, at the time of enrollment, opted for a repeat MBN procedure (at the same level and side). A positive MBB as determined by the Principal Investigator (PI) is required for all patients that was performed either at the time of the original diagnosis or at the time of pain recurrence. Thereby, for patients with a new diagnosis of chronic zygapophysial joint neck- or lower back pain (not treated with MBN in the past), a positive diagnostic MBB will be required. For patients with pain recurrence, a positive diagnostic MBB that was performed at the time of the original pain diagnosis, i.e., before the first MBN treatment, will be considered sufficient. (If no diagnostic MBB was performed at the time of the original diagnosis, a diagnostic MBB at the time of recurrence will be required.) The diagnosis will be reviewed by the Principal Investigator (PI) during Screening who will consider the timeline and diagnostic rigor of prior medical findings and tests in conjunction with the evaluation performed during screening (history and physical exam). PI agreement with the diagnosis (at their discretion) is required for the participant to meet this criterion.
✓. Ambulatory
✓. Body weight ≥48 kg
✓. Able to understand and comply with the study
✓. Willing to provide written informed consent
What they're measuring
1
Safety of ITX24-01 or placebo delivered locally by the medial branch block (MBB) route in adult participants with severe chronic zygapophysial joint pain
Timeframe: During the screening period, on the day of ITX24-01 administration, and up to 6 weeks of follow-up.
2
Tolerability of ITX24-01 or placebo delivered locally by the medial branch block (MBB) route in adult participants with severe chronic zygapophysial joint pain
Timeframe: At pre-specified time points up to 6 hours after administration of the investigational medicinal product (IMP).
. Patients with zygapophysial joint neck- or lower back pain affecting a single joint (who require two injection of the IMP) are allowed in any group of the study (including Group 1). Patients with zygapophysial joint neck- or lower back pain affecting two joints at adjacent levels (who require three injection of the IMP) are allowed in Groups 2, 3 and 4 only.
Exclusion criteria
✕. Pregnant or breastfeeding
✕. Diagnosis of thoracic chronic zygapophysial joint pain
✕. Allergy or hypersensitivity to lidocaine, bupivacaine or iodinated radiographic contrast media
✕. Clinical history of angina, myocardial infarction or stroke experienced within the past year
✕. If taking warfarin, an INR ≥ 3.0
✕. Suicidal ideation or behavior (SIB)
✕. Pathological ECG. Exclude subjects with a marked baseline QTc prolongation defined as QTc \>470 ms in males or \>480 ms in females; or as QTc \>450 ms in males or \>470 ms in females with any additional torsades risk factors (heart failure, hypokalaemia, concomitant QT-prolonging drugs).
✕. Any other medical condition identified during screening that in the PI's judgement may preclude the safe performance of the study procedure